What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response.

摘要: Imatinib is widely recognized as the standard of care in first-line treatment chronic myeloid leukemia (CML); however, resistance can limit its long-term benefits. Early identification loss response to imatinib therefore important for optimal management patients with this type leukemia. Cytogenetic and molecular responses during first 12 months have been shown predict future (complete cytogenetic major response) reduce disease progression. The degree early reduction BCR-ABL levels after commencing therapy a good indicator subsequent response. Monitoring kinase domain mutations should also be considered suboptimal or those who demonstrate resistance. Modification strategy required if there Dasatinib nilotinib are most extensively studied second-generation tyrosine inhibitors, currently approved treating following failure.